JP2009524422A - 結合分子３ - Google Patents

結合分子３ Download PDF

Info

Publication number
JP2009524422A
JP2009524422A JP2008551872A JP2008551872A JP2009524422A JP 2009524422 A JP2009524422 A JP 2009524422A JP 2008551872 A JP2008551872 A JP 2008551872A JP 2008551872 A JP2008551872 A JP 2008551872A JP 2009524422 A JP2009524422 A JP 2009524422A
Authority
JP
Japan
Prior art keywords
polypeptide
binding
domain
domains
binding complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008551872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009524422A5 (enExample
Inventor
グロスヴェルド，フランクリン・ジェラルダス
ヤンセンス，リハルト・ウィルヘルム
ドラベク，ドゥブラヴカ
クレイグ，ロジャー・キングドン
Original Assignee
エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム filed Critical エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム
Publication of JP2009524422A publication Critical patent/JP2009524422A/ja
Publication of JP2009524422A5 publication Critical patent/JP2009524422A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008551872A 2006-01-25 2007-01-25 結合分子３ Pending JP2009524422A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0601513.5A GB0601513D0 (en) 2006-01-25 2006-01-25 Binding molecules 3
PCT/GB2007/000258 WO2007085837A1 (en) 2006-01-25 2007-01-25 Binding molecules

Publications (2)

Publication Number Publication Date
JP2009524422A true JP2009524422A (ja) 2009-07-02
JP2009524422A5 JP2009524422A5 (enExample) 2010-03-11

Family

ID=36060850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008551872A Pending JP2009524422A (ja) 2006-01-25 2007-01-25 結合分子３

Country Status (13)

Country Link
US (1) US20090169548A1 (enExample)
EP (1) EP1989229A1 (enExample)
JP (1) JP2009524422A (enExample)
KR (1) KR20080106201A (enExample)
CN (1) CN101472946A (enExample)
AU (1) AU2007209130A1 (enExample)
BR (1) BRPI0706737A2 (enExample)
CA (1) CA2637945A1 (enExample)
GB (1) GB0601513D0 (enExample)
RU (1) RU2008134519A (enExample)
TW (1) TW200808824A (enExample)
WO (1) WO2007085837A1 (enExample)
ZA (1) ZA200806492B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530009A (ja) * 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． 異常細胞を標的とする多重特異性結合分子
JP2015519055A (ja) * 2012-05-17 2015-07-09 カイマブ・リミテッド 二重特異性免疫グロブリンまたは超変異重鎖のみの免疫グロブリンのｉｎｖｉｖｏでの生成のためのトランスジェニック非ヒト脊椎動物
JP2020537506A (ja) * 2017-10-04 2020-12-24 アムジエン・インコーポレーテツド トランスサイレチン免疫グロブリン融合物
US10946104B2 (en) 2012-01-13 2021-03-16 Apo-Tb.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2535350B1 (en) 2007-09-26 2018-01-24 UCB Biopharma SPRL Dual specificity antibody fusions
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
AU2012311286B2 (en) 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
IN2014CN03887A (enExample) * 2011-10-27 2015-10-16 Genmab As
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
CN102851338A (zh) * 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
GB2518221A (en) * 2013-09-16 2015-03-18 Sergej Michailovic Kiprijanov Tetravalent antigen-binding protein molecule
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016087416A1 (en) * 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
GB2576914A (en) * 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
US20220227888A1 (en) 2019-06-07 2022-07-21 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
CN113461824A (zh) * 2020-03-31 2021-10-01 普米斯生物技术(珠海)有限公司 一种构建多特异性抗体的平台
CA3184351A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
MX2023006573A (es) 2020-12-03 2023-06-19 Amgen Inc Constructos de inmunoglobulina con multiples dominios de union.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002781A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
WO2006008548A2 (en) * 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900956A2 (hu) * 1998-04-09 2002-04-29 Aventis Pharma Deutschland Gmbh. Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002781A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
WO2006008548A2 (en) * 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012024431; Ｊ　Ｂｉｏｌ　Ｃｈｅｍ Ｖｏｌ．２７８，　Ｎｏ．４８, 2003, ｐ．４７８１２-４７８１９ *
JPN6012024432; Ｊ　Ｂｉｏｌ　Ｃｈｅｍ Ｖｏｌ．２７６，　Ｎｏ．１０, 2001, ｐ．７３４６-７３５０ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530009A (ja) * 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． 異常細胞を標的とする多重特異性結合分子
US11098115B2 (en) 2011-09-29 2021-08-24 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
US10946104B2 (en) 2012-01-13 2021-03-16 Apo-Tb.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
JP2015519055A (ja) * 2012-05-17 2015-07-09 カイマブ・リミテッド 二重特異性免疫グロブリンまたは超変異重鎖のみの免疫グロブリンのｉｎｖｉｖｏでの生成のためのトランスジェニック非ヒト脊椎動物
JP2020537506A (ja) * 2017-10-04 2020-12-24 アムジエン・インコーポレーテツド トランスサイレチン免疫グロブリン融合物

Also Published As

Publication number Publication date
AU2007209130A1 (en) 2007-08-02
ZA200806492B (en) 2009-12-30
BRPI0706737A2 (pt) 2011-04-05
RU2008134519A (ru) 2010-02-27
CA2637945A1 (en) 2007-08-02
WO2007085837A1 (en) 2007-08-02
GB0601513D0 (en) 2006-03-08
CN101472946A (zh) 2009-07-01
US20090169548A1 (en) 2009-07-02
TW200808824A (en) 2008-02-16
EP1989229A1 (en) 2008-11-12
KR20080106201A (ko) 2008-12-04

Similar Documents

Publication Publication Date Title
US20090169548A1 (en) Binding molecules
US20240174745A1 (en) Antibody Constructs for CLDN18.2 and CD3
JP5888893B2 (ja) 結合分子
ES2315664T3 (es) Anticuerpos de dominio unico (dab) pegilados.
ES2780948T3 (es) Proteínas de fusión de inmunoglobulinas en hélice enrollada y composiciones de las mismas
KR102378289B1 (ko) IgA 다중-특이적 결합 분자
TWI907375B (zh) 多肽、蛋白質複合物及其製造方法
CN115427446A (zh) Wnt超级激动剂
WO2008122886A2 (en) Transgenic non-human mammal with homodimeric vh binding complex
JP2023548345A (ja) クリッピング率の低減した抗原結合ドメイン
MX2008009686A (en) Binding molecules
JP2025528101A (ja) 多重特異性ポリペプチド複合体
TW202615479A (zh) 細胞激素受體促效劑
AU2011203061B2 (en) Binding molecules
AU2024207355A1 (en) Multi-specific polypeptide complexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090407

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120515

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121010